This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Rare CNS Tumors Outcomes &Risk | MicrobiomeTrials
← Back to trials NCT03251989
Rare CNS Tumors Outcomes &Risk Completed OBSERVATIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2017-08-21Est. Completion: 2025-05-06
Enrollment target: 326 participantsLocations National Cancer Institute (NCI)/ Neuro-Oncology Branch, Bethesda, Maryland, United States Other microbiome trials you might be interested in Recurrent Meningioma, Grade I and Grade II
In this study, patients with recurrent grade I and grade II meningiomas will receive a daily dose of ceritinib for abour…
Montreal, Canada Est. completion Jan 2031
Central Nervous System Neoplasms Glioblastoma Gliosarcoma, Adult Anaplastic Oligodendroglioma Anaplastic Astrocytoma Pilocytic Astrocytoma Oligodendroglioma Gliomatosis Cerebri
Pleomorphic Xanthoastrocytoma
Anaplastic Pleomorphic Xanthoastrocytoma
Diffuse Midline Glioma, H3 K27M-Mutant
Ependymoma
Ependymoma, Anaplastic
Medulloblastoma
Teratoid Rhabdoid Tumor
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors
Anaplastic Meningioma
Atypical Meningioma
Choroid Plexus Neoplasms
Pineal Tumor
Diffuse Astrocytoma
Glial Tumor
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and …
Bethesda, United States Est. completion Mar 31, 2027